The Analysis of Covid-19 Vaccine Influence on Pfizer Business

Abstract

Various sectors of the global economy have been affected to varying degrees by the Newcastle pneumonia outbreak, and the pharmaceutical industry is no exception. Vaccines, which are essential for fighting the epidemic, have brought new growth opportunities to many pharmaceutical companies. In this paper, Pfizer is adopted as an example to analyze its business strategies and revenue changes before and after the outbreak using the literature research method. After that, this paper compares Pfizer and other companies from three perspectives of Profitability, Liquidity and Revenue, and concludes that Pfizer's business is more stable and sustainable, and vaccines bring Pfizer huge profits.Finally, Pfizer's current competitive advantages are analyzed from three perspectives: patents, global coverage of vaccines, and business strategies, and further investment judgments are drawn from policy and technology disputes. Overall, Pfizer can quickly make strategic adjustments and actively respond to difficulties when it is in trouble, and still maintain good business conditions during the epidemic, making it a good investment value, while also improving its own R&D capabilities and continuing to expand its advantages.